Trial
NCT04273555
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Alabama at Birmingham
Collaborators
—
Condition
HER2-positive Breast Cancer
Intervention
[18F]-FDG
Why stopped
Unable to recruit for this study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-01